Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin and social attention in healthy controls and patients with Parkinson's disease
2018-002877-23Phase 2Terminated
- Sponsor
- Medical University of Innsbruck
- Start
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin in Parkinson's disease (PD), sponsored by Medical University of Innsbruck. Primary endpoint: Number of fixations towards social stimuli in naturalistic scenes. Started Dec 2018; status: terminated.
02
Drugs
oxytocin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2018-002877-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002877-23.